Auvelity is the first oral rapid-acting antidepressant for adults with major depressive disorder. In a six-week trial, Auvelity started working for some people as early as one week compared to a placebo. It was approved by the U.S. Food and Drug Administration in 2022.
Check our best Auvelity prices
Auvelity
Dextromethorphan hydrobromide and bupropion hydrochloride
Dopamine/norepinephrine reuptake inhibitor and NMDA antagonist
Extended-release tablet
By mouth
Auvelity is approved for adults with major depressive disorder.
Auvelity is a fast-acting antidepressant with improvement noted after one week versus other antidepressants, which can take four to eight weeks.
Auvelity is less likely to cause weight gain than other antidepressants.
It is expensive with no generic version available.
Extended-release tablet
45 mg dextromethorphan hydrobromide / 105 mg bupropion hydrochloride
Starting dose for depression in adults:
1 tablet once per day in the morning
After three days of treatment:
Increase to maximum recommended dosage of 1 tablet twice per day separated by at least 8 hours
Do not exceed two doses within the same day
Auvelity
45-105mg tablet extended release
Take Auvelity as instructed by your healthcare provider.
Do not take more than two tablets of Auvelity in 24 hours.
Do not take more than one dose of Auvelity at a time.
Do not change your dose or stop taking Auvelity without talking to your healthcare provider first.
Swallow Auvelity tablets whole.
Seek professional medical advice if you take too much Auvelity.
Do not take an extra dose to make up for a missed dose of Auvelity.
Wait and take your next dose at the regular time.
Do not take more than 1 dose of Auvelity at a time.
Do not take Auvelity if you:
Have a seizure disorder
Are currently or previously diagnosed with bulimia or anorexia nervosa
Abruptly discontinue alcohol, benzodiazepines, barbiturates, and antiepileptic drugs
Use MAOIs or have used MAOIs within 14 days of treatment with Auvelity
Are sensitive to bupropion, dextromethorphan, or other ingredients of Auvelity
Auvelity is not recommended for use in:
Pregnant women
Breastfeeding women
People with severe renal impairment
People with severe hepatic impairment
Increased risk of suicidal thoughts and behavior in pediatric and young adult patients taking antidepressants.
Bupropion (an active ingredient in Auvelity) can cause seizures.
Elevated blood pressure and hypertension.
Increased risk of mania or hypomania, particularly in patients with bipolar disorder or those with risk factors for bipolar disorder.
Increased risk of psychosis and other neuropsychiatric reactions.
Auvelity may cause angle-closure glaucoma.
Dizziness was reported by 14% of people taking Auvelity in controlled studies (compared to 6% of patients on placebo).
Using Auvelity with SSRIs or tricyclic antidepressants may cause serotonin syndrome.
Based on animal studies, Auvelity may cause harm to the fetus when taken during pregnancy.
Auvelity should not be taken with:
Strong CYP2D6 inhibitors
Strong CYP2D6 inducers
CYP2D6 substrates
Digoxin
Drugs that lower seizure threshold
Dopaminergic drugs
Note: Auvelity can cause false-positive urine test results for amphetamines.
Auvelity can cause serious side effects. Please contact your doctor immediately or go the your local ER if you develop any of the following:
Suicidal thoughts and behaviors in adolescents and young adults
Seizure
Significantly elevated blood pressure
Activation of mania or hypomania
Psychosis and other neuropsychiatric reactions
Severe eye pain or blurred vision
Serotonin syndrome
Auvelity can also cause less serious side effects. Many of these side effects are mild and subside after the first week. If they persist, please inform your doctor. These side effects include:
Dizziness
Headache
Diarrhea
Drowsiness
Dry mouth
Sexual dysfunction
Excessive sweating
Nausea
Anxiety
Constipation
Decreased appetite
Insomnia
Joint pain
Fatigue
Paraesthesia (pins and needles sensation)
Auvelity prescribing information, FDA (2022)
About Auvelity, Axsome Therapeutics, Inc.
Efficacy and safety of AXS-05 (dextromethorphan-bupropion) in patients with major depressive disorder: a phase 3 randomized clinical trial (GEMINI), The Journal of Clinical Psychiatry (2022)
Peter Lourgos, MD, JD, was born and raised near Chicago. During his college years, he developed an interest in the intersection of law and medicine and subsequently enrolled in a dual degree medicine/law program at Southern Illinois University. He completed residency training in general and forensic psychiatry and is board-certified in both areas.
After completing his training, he worked as a criminal forensic psychiatrist for the Circuit Court of Cook County in Chicago, where he evaluated individuals charged with various crimes and reported his findings to the court. During this time, he served as a Clinical Associate Professor of Psychiatry, where he trained both medical students and resident physicians.
He has also served as a medical consultant to several large insurance providers.
Dr. Lourgos maintains an active clinical practice and sees patients for a variety of mental health concerns, including mood disorders, anxiety disorders, PTSD, and trauma. He has a passion for teaching others about mental health issues as it contributes to positive overall health and decreases the stigma often associated with mental health diagnoses.
...Health education, drug info, wellness & more
Prescription savings vary by prescription and by pharmacy, and may reach up to 80% off cash price. This is a medical discount plan. This is NOT insurance. This program offers you the opportunity to locate providers of various types of medical services who will offer their services to you at discounted rates. The range of discounts for medical or ancillary services provided under the plan will vary depending on the type of provider and service received. You are fully responsible for paying for all health care services but will be entitled to receive a discount from those health care providers in accordance with the specific pre-negotiated discounted fee schedule. This program does not guarantee the quality of the services or procedures offered by the providers. Except for prescription drugs which you will pay directly to the pharmacy at the time of purchase, all other services received through a program provider will be charged to the credit card on file in your member account. The charge will include an administrative fee for use of the program. Towers Administrators LLC is the licensed discount medical plan organization with its administrative office located at 4510 Cox Road, Suite 111, Glen Allen, VA 23060. SingleCare Services, LLC is the marketer of the discount medical plan organization including its website, singlecare.com, with its corporate office located at 99 High Street, Suite 2800, Boston, MA 02110. For additional information, including an up-to-date list of providers, or assistance with any issue related to program membership, please contact member support any time at www.singlecare.com, or by calling toll-free 844-234-3057, 24 hours, 7 days a week (except major holidays). Pharmacy names, logos, brands, and other trademarks are the property of their respective owners.
Blog articles are not medical advice. They are intended for general informational purposes and are not meant to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. If you think you may have a medical emergency, immediately call your physician or dial 911.
© 2025 SingleCare Administrators. All rights reserved
© 2025 SingleCare Administrators. All rights reserved